Abstract Accumulating evidence indicates that microparticles (MPs) are important mediators of the interaction between cancer and the hemostatic system. We conducted a large prospective cohort study to determine whether the number of circulating procoagulant MPs is elevated in cancer patients and whether the elevated MP levels are predictive of occurrence of venous thrombembolism (VTE). We analyzed plasma samples of 728 cancer patients from the ongoing prospective observational Vienna Cancer and Thrombosis Study. Study endpoint was the occurrence of symptomatic VTE. Sixty-five age-and sex-matched healthy controls were recruited for defining the cut-off point for elevated MPs (4.62 nanomolar phosphatidylserine [nM PS]), which was set at the 95th percentile of MP levels in healthy controls. The measurement of MPs was performed after capture onto immobilized annexin V, and determination of their procoagulant activity was quantified with a prothrombinase assay. During a median observation period of 710 days, 53 patients developed VTE. MP levels (nM PS) were significantly higher in cancer patients than in healthy controls (median [25th- 
Introduction
Circulating procoagulant microparticles (MPs) are phosphatidylserine (PS)-rich, small vesicles with a diameter of 0.1 μm to 1 μm which are emitted from cell membranes into the blood when cells are activated or undergo apoptosis. The majority of MPs in plasma are derived from platelets [1] , erythrocytes [2] , endothelial cells [3] , lymphocytes [4] , monocytes [5] , and smooth muscle cells [6] . An important role of MPs in the hemostatic system has been proposed because MPs provide a negatively charged surface for the aggregation and subsequent activation of coagulation factors and promote coagulation via the expression of coagulation proteins and adhesion molecules on their surface [7] [8] [9] [10] . Experimental studies have demonstrated that MPs are involved in the pathophysiology of thrombosis [11] . It has been shown that a subgroup of MPs is guided to a developing thrombus through the interaction of P-selectin glycoprotein ligand-1 (PSGL-1), which is present on MPs, and P-selectin, which is expressed on activated platelets and endothelial cells. The accumulation of MP-bound tissue factor (TF) further supports thrombus growth [12] .
Clinical studies have reported elevated MP levels in different thrombotic disorders [11] . Yet, results are conflicting regarding the clinical relevance of MPs in venous thromboembolism (VTE). While highly elevated MP levels were measured shortly after an acute VTE event in cancer and non-cancer patients [13, 14] , MP levels were not elevated 3 months after a VTE event in a high-risk population of non-cancer patients with a history of recurrent VTE [15] . Although cancer patients have a fourto sevenfold increased risk of VTE and VTE is the second leading cause of death in this population, after cancer itself, [16] [17] [18] large prospective clinical studies investigating the predictive role of MPs in cancer-associated VTE are still lacking.
As the pathophysiology of cancer-associated VTE is not fully understood and laboratory parameters to predict cancer-associated VTE are scarce, attention in recent research activities has been focused on MPs as mediators of the interaction between cancer and the hemostatic system. Accumulating evidence indicates that MPs contribute to the development of VTE in cancer patients [7] . High levels of circulating MPs were found in breast cancer [19] , gastric cancer [20] , and pancreatic cancer patients [13] compared to healthy individuals, and TF-positive MPs were postulated as candidate biomarkers for the development of cancerassociated VTE [21, 22] .Therefore, the aim of this prospective observational cohort study was to determine whether baseline levels of MPs are elevated in cancer patients with different tumor types compared to sex-and age-matched healthy individuals and whether elevated MP levels have a predictive role in the occurrence of VTE in prospectively followed cancer patients.
Design and methods

Study population
The study protocol was approved by our local Ethics Committee. Informed consent was signed before patients and healthy individuals were included in this study. This study was designed as a case-control study as part of the ongoing observational Vienna Cancer and Thrombosis Study (CATS), which was initiated in 2003. First data of this study were published in 2008 and 2009 [23] [24] [25] . Plasma samples of 728 cancer patients with newly diagnosed cancer or progression of disease after complete or partial remission, including malignancies of the brain, breast, lung, stomach, colon, pancreas, kidney, prostate, hematological malignancies (multiple myeloma, high-and low-grade lymphoma) or other sites (mainly of the gynecologic system and sarcoma) were analyzed. Main patients' characteristics are listed in Table 1 . At study inclusion, patients underwent a structured interview on their medical history and data on the site of tumor, histology, and tumor stage were documented. Patients were followed prospectively and information on the course of disease and on the occurrence of VTE was collected for every patient at 3-month intervals. Patients were instructed to In case of death, data on the time and the cause of death including autopsy protocols were collected. Each patient was followed over a 2-year period or until the occurrence of VTE, death, or loss of follow-up. We recruited 65 age-and sex-matched healthy control subjects without a history of arterial or venous thrombosis and cancer from the same geographic region and ethnic backgrounds as our patients. Based on their MP levels, we defined the cut-off point for elevated MPs, which was set at the 95th percentile of the MP levels in our healthy control group.
Blood sampling and laboratory methods
Venous blood samples were drawn into citrate vacuum tubes (Vacuette, Greiner-Bio One, Kremsmuenster, Austria) by atraumatic and sterile antecubital venipuncture on the day of study entry. The citrated blood was centrifuged (Rotanta/TRC, Hettich, Tuttlingen, Germany) at 1,500×g for 15 min to get platelet-poor plasma. Platelet-free plasma (PFP) was obtained by a second centrifugation step (Eppendorf, Hamburg, Germany) at 13,400×g for 2 min. The centrifugation of each sample was performed within 1 h after blood sampling and the freezing of each sample within 1 h after centrifugation. Plasma aliquots were stored at −80°C until assays were performed in series.
MPs were captured by immobilized annexin V as previously described [26] . In brief, biotinylated annexin V (annexin V Bi ; Roche Diagnostics, Mannheim, Germany) was insolubilized onto streptavidin-coated microtitration plates (Roche Diagnostics, Mannheim, Germany). The plates were washed three times with TBS-Ca 2+ (50 mM Tris buffer, pH 7.5 containing 120 mM NaCl, 2.7 mM KCl, and 1 mM CaCl 2 ). The 300-μl aliquots of PFP were thawed and thrombin inhibitor (30 μM PPACK; Merck, Darmstadt, Germany) and factor Xa inhibitor (30 μM 1.5-Dns-GGACK; Merck, Darmstadt, Germany) were added. We then incubated 100 μl PFP/well for 30 min at 37°C. Each sample was measured in duplicate. After four washing steps, the anionic phospholipid content was determined by a prothrombinase assay. In this assay, immobilized MPs were incubated in a final volume of 150 μl with factor Va (250 pM; American Diagnostica, Stamford, USA), Xa (9.3 pM; Hyphen BioMed, Andresy, France), prothrombin (0.7 μM; Hyphen BioMed, Andresy, France), and CaCl 2 (2.3 mM) for 15 min at 37°C. Then, Chromozym TH (1.5 mM; Roche Diagnostics, Mannheim, Germany), a chromogenic substrate for thrombin, was added and the solution was incubated for 4 min. The chromogenic substrate was cleaved by thrombin. Change of color was measured photometrically. Linear absorbance changes were recorded at 405 nm using a microtitration plate reader (MR 7000, Dynatech, Guernsey, Great Britain).
In the method first described by Aupeix et al. [26] , a kinetic software was used for data analysis. To make this method applicable on a standard laboratory photometer, the color reaction was stopped after 4 min by the addition of EDTA (5 mM). As the color development reaction followed a Michaelis-Menten kinetic, we compared our measurements to standard curves by means of non-linear regression analysis. Results were expressed as nanomolar phosphatidylserine equivalent (nM PS) by reference to a standard curve that we had constructed by using phospholipids of defined composition (33% PS and 67% phosphatidylcholine (PC)) as described by Pigault et al. [27] . Phospholipids were quantified by the Stewart assay [28] . When MPs were present, the reaction was significantly accelerated because of the high amount of PS present on MPs.
Statistical analysis
Continuous variables were described with the median and the 25th-75th percentile. The median follow-up time was calculated with the reverse Kaplan-Meier method. A Wilcoxon test was applied to test differences in the distribution of MPs between cancer patients and controls.
Elevated levels of MPs were defined as those exceeding the 95th percentile of healthy controls. Kaplan-Meier analysis and a log-rank test were used to compare the cumulative probability of VTE between cancer patients with elevated or non-elevated MPs.
Univariate and multivariable Cox regression analyses were applied to calculate the risk of VTE from study inclusion until first thrombosis. Data were censored at last follow-up, patient's death, or at end of follow-up after 2 years. The multivariable Cox regression analysis comprised the following parameters: MPs, age, sex, surgery, chemo-, and radiotherapy. The covariate of main interest was elevated MPs. We assumed that surgery, chemotherapy, and radiotherapy would not only modify the VTE risk at the exact time point of the procedure, but also for a certain time period beyond six consecutive weeks for surgery and four for chemo-or radiotherapy (from the first day of a treatment cycle until the last day plus 4 weeks). Timedependent effects on the VTE risk were modeled by inclusion of these three time-dependent dichotomous variables into the multivariable Cox regression model. Furthermore, the analysis was adjusted for age at study inclusion and sex. The multivariable Cox regression model was tested for all pairwise interactions and interactions with log(time) by means of candidate variables. As no significant interaction was found (p value smaller than 0.01), no interaction was added.
A p value smaller than 0.05 was regarded as statistically significant. All calculations were conducted with SAS 9.2.
Results
Circulating procoagulant MP in patients and controls
In this study, plasma levels of circulating procoagulant MPs were measured in 728 patients with solid and hematological malignancies and in 65 healthy individuals. The baseline characteristics of patients and controls are given in Table 1 Fig. 1 ). The cut-off point for elevated MPs was set at ≥4.62 nM PS, which represented the 95th percentile of MP levels in the control individuals of our study. Elevated MPs were found in 327 (44.9%) cancer patients.
Association of circulating MPs with the occurrence of VTE in cancer patients
During a median observation period of 710 days (25th-75th percentile, 262-731) 53 (7.3%) patients developed VTE. The overall cumulative probability of VTE in cancer patients was 5.9% after 6 months and 7.3% after 1 year. The characteristics of patients who developed VTE are given in Table 2 .
There was no statistically significant difference of MP levels between cancer patients with localized disease and cancer patients with distant metastasis at study inclusion ( Fig. 1 Box plot analysis of MP levels (nM PS) in healthy controls and cancer patients. The boundaries of the box represent the 25th and the 75th percentiles, respectively. The line inside the box marks the median. The 10% and the 90% percentiles were used for whiskers.
Open circles represent outliers
In patients with elevated MP levels, cumulative probabilities of VTE were 5.2% after 6 months and 6.8% after 1 year, and in those with non-elevated MP levels, they were 6.4% after 6 months and 7.7% after 1 year, respectively (log-rank test, p=0.968).
Discussion
In this study, we measured circulating procoagulant MPs in 728 cancer patients who were followed prospectively for a median of 710 days and in a control group of age-and sexmatched healthy individuals. In line with previous reports, MP levels at study inclusion were significantly higher in the group of cancer patients than in healthy controls without cancer [13, 19, 20, 29] . MPs were also analyzed for their potential of being a predictive parameter for the occurrence of VTE in cancer patients. However, MP levels were not found to be predictive of VTE in cancer patients.
Consistent with previous studies, in our study, we observed the highest VTE rates in patients with brain tumors (high-grade glioma) [30] . However, we did not find higher MP levels in the subgroup of patients with brain tumors compared to other tumor entities. The high risk of VTE in brain tumors is not fully understood. VTE is a multifactorial disease and in cancer patients several risk factors such as immobilization, tumor subtype, tumor size, chemotherapy, or radiotherapy and many other acquired or inherited VTE risk factors contribute to the very high VTE risk. This may be especially true for brain tumor patients in whom the high VTE risk exceeds the postoperative period and stays high throughout the course of disease. [31] [32] [33] [34] .
Up to date, several methods for the measurement of MPs have been developed in order to quantify circulating MPs. Most studies used either flow cytometry to measure the number of MPs, or functional chromogenic assays were deployed to determine the procoagulant potential of MPs [35] . In our large prospective study, we used a functional chromogenic assay in a solid phase for MP detection. For the construction of standard curves, phospholipids of defined composition were used (33% PS and 67% PC). Interestingly, recent studies showed that the phospholipid composition of circulating procoagulant MPs varies depending on type of originating cell and type of stimulation [36] [37] [38] . Therefore, great variations of the PS and PC distribution on the surface of circulating MPs of different origins may be possible, especially tumor-derived MPs may have a completely different phospholipid composition as the phospholipids used in our standard curves. Nevertheless, this prothrombinase assay is a wellestablished method that had previously been used in several different clinical studies for the assessment of circulating procoagulant MPs in patients with a variety of diseases, such as sepsis [39] , HIV [26] , type 1 and type 2 diabetes [40] , acute coronary syndrome [41] , VTE [14, 42] , and preeclampsia [43] . Yet, up to date, there are no studies applying this functional prothrombinase assay in a solid phase in cancer. Using this method, we detected higher MP levels in cancer patients than in healthy individuals, but the difference between MP levels of cancer patients who developed future VTE and those who did not was not statistically significant.
As freeze-thawing cycles might increase the number of circulating MPs [44] , a limitation of the study might be that we used frozen plasma samples for the determination of MPs. However, samples of cancer patients and controls were freshly thawed and treated equally and different preanalytical conditions can be excluded.
Recently, new assays for the measurement of TF-positive MPs or MP-associated TF activity have been established that so far have been predominantly performed in cancer patients. Hron et al. measured twofold higher levels of TFpositive MPs in colorectal cancer patients compared to healthy controls and reported that TF-positive MPs correlated with elevated D-dimer levels, which is a marker for activation of coagulation [29] . In two small studies, functional chromogenic assays were used to compare MPassociated TF activity in cancer patients with and without acute VTE. Tesselaar et al. measured an elevated MPassociated TF activity in metastatic breast cancer patients and metastatic pancreatic cancer patients who presented with acute VTE compared to cancer patients without VTE [13] . Strikingly, no MP-associated TF activity was found in non-cancer patients who had suffered from acute VTE. Also, Manly et al. detected higher MP-associated TF activity levels in 53 cancer patients with different tumor types and acute VTE than in 13 cancer patients without VTE [42] . Furthermore, Zwicker et al. applied a newly developed method, the impedance flow cytometry, and showed elevated numbers of TF-positive MPs in 60% of cancer patients with acute VTE compared to 27% of cancer patients without VTE [10] .In contrast to the abovementioned studies, in our large prospective study, we measured baseline MP levels of cancer patients and followed them over a 2-year period or until occurrence of VTE, or death, or loss of follow-up in order to find parameters that might be predictive of cancer-associated VTE. According to our study protocol, cancer patients with acute VTE at least 3 months prior to study inclusion were not enrolled in order to exclude the effect of an acute VTE event on MP levels and other laboratory parameters. In our study, MPs were quantified by measuring the PS content on the MP surface after capture onto immobilized annexin V and by determining their procoagulant activity with a prothrombinase assay. PS was reported to be a highly procoagulant phospholipid [11] , but our results do not support a predictive role of PS-exposing MPs for the occurrence of VTE in cancer patients. Whether MPs that additionally express high levels of TF on their surface might be predictive of cancer-associated VTE remains to be further elucidated in large prospective studies.
In conclusion, we found that MP levels in cancer patients were elevated compared to healthy individuals. However, with the prothrombinase assay, we did not find a significant association between circulating procoagulant MPs and the risk of developing VTE in cancer patients. It has to be considered that VTE is a complex multifactorial process and that a plethora of pathologic changes occurs in the hemostatic system of cancer patients. The role of procoagulant MPs in cancer-associated VTE still needs to be addressed in other large prospective studies. These studies should also focus on the measurement of TFpositive MPs as a predictive parameter because recent experimental and clinical research indicates a potential role of this specific MP subpopulation in the pathogenesis of cancer-associated VTE.
